Glioblastoma (GBM) is the most common and aggressive malignant brain tumor in adults and is poorly controlled. Previous studies have shown that both macrophages and angiogenesis play significant roles in GBM progression, and co-targeting of CSF1R and VEGFR is likely to be an effective strategy for GBM treatment. Therefore, this study developed a novel and selective inhibitor of CSF1R and VEGFR, SYHA1813, possessing potent antitumor activity against GBM. SYHA1813 inhibited VEGFR and CSF1R kinase activities with high potency and selectivity and thus blocked the cell viability of HUVECs and macrophages and exhibited anti-angiogenetic effects both in vitro and in vivo. SYHA1813 also displayed potent in vivo antitumor activity against GBM in immune-competent and immune-deficient mouse models, including temozolomide (TMZ) insensitive tumors. Notably, SYHA1813 could penetrate the blood–brain barrier (BBB) and prolong the survival time of mice bearing intracranial GBM xenografts. Moreover, SYHA1813 treatment resulted in a synergistic antitumor efficacy in combination with the PD-1 antibody. As a clinical proof of concept, SYHA1813 achieved confirmed responses in patients with recurrent GBM in an ongoing first-in-human phase I trial. The data of this study support the rationale for an ongoing phase I clinical study (ChiCTR2100045380).

To evaluate the feasibility of the somatic acupressure (SA) for managing the fatigue-sleep disturbance-depression symptom cluster (FSDSC) among breast cancer (BC) survivors and its preliminary effects. In this Phase II randomized controlled trial (RCT), 51 participants were randomised evenly into the true SA group, sham SA group, and usual care group. All the participants received usual care. The two SA groups performed additional true or sham self-acupressure daily for seven weeks. The primary outcomes related to the assessment of participants' recruitment and compliance with study questionnaires and interventions. Clinical outcomes assessed the preliminary effects of SA on fatigue, sleep disturbance, depression, and quality of life. Semi-structured interviews were undertaken to capture participants' experiences of participating in this study. The statistical effects of the intervention on the outcomes were modelled in repeated measures ANOVA and adjusted generalized estimating equations. Forty-five participants completed the SA intervention. No adverse events were reported. Over 85% of the participants could sustain for 25 days or more and 15 min or more per session, but the adherence to the intervention requirement was yet to improve. The group by time effect of the FSDSC and depression were significant (p < 0.05). Qualitative findings showed that participants positively viewed SA as a beneficial strategy for symptom management. The SA intervention protocol and the trial procedures were feasible. The results demonstrated signs of improvements in targeted outcomes, and a full-scale RCT is warranted to validate the effects of SA on the FSDSC.

To summarize nonpharmacological interventions and assess their effects on symptom clusters and quality of life (QoL) in breast cancer (BC) survivors. Seven English and three Chinese electronic databases and three clinical trial registries were searched from January 2001 to August 2023. A narrative approach was applied to summarize the data. The primary outcome was symptom clusters measured by any patient-reported questionnaires, and the secondary outcomes were QoL and intervention-related adverse events. Six published articles, one thesis, and one ongoing trial involving 625 BC survivors were included. The fatigue-sleep disturbance-depression symptom cluster was the most frequently reported symptom cluster among BC survivors. The nonpharmacological interventions were potentially positive on symptom clusters and QoL among the BC survivors. However, some of the included studies exhibited methodological concerns (e.g., inadequate blinding and allocation concealment). The intervention protocols in only two studies were developed following a solid evidence-based approach. Adverse events related to the targeted interventions were reported in six included studies, with none performing a causality analysis. The nonpharmacological interventions could be promising strategies for alleviating symptom clusters in BC survivors. Future studies should adopt rigorously designed, randomized controlled trials to generate robust evidence. INPLASY202380028

This systematic review aimed to identify the unmet needs of culturally and linguistically diverse (CALD) cancer survivors in Australia, defined as individuals from non-English-speaking countries and/or those who do not speak English at home. It also examined the factors associated with the identified unmet needs, along with suggestions and recommendations to address them. Seven databases were systematically searched from their inception to November 2024. Studies focused on the unmet needs of CALD cancer survivors in Australia, regardless of the study design, were included. The Mixed Methods Appraisal Tool was used to assess the methodological quality of the included studies, and content analysis and descriptive analysis were adopted for data analysis. Six studies were included, comprising two quantitative and four qualitative studies. The quality of the included studies was moderate to high, with four included studies meeting 100 % of the criteria. The most reported unmet needs among CALD cancer survivors were related to the health system and information, followed by psychological well-being, and patient care and support. Language barriers and cultural beliefs were the main factors associated with their unmet needs. Translated written material with culturally tailored information was the most recommended approach to address their unmet needs. CALD cancer survivors in Australia experienced unmet needs, especially culturally specific information related to cancer rehabilitation. Providing culturally tailored health resources and information in their languages or establishing multilingual platforms would effectively enhance health information provision and address unmet needs. Policymakers should consider transcultural training for healthcare providers. INPLASY2024110074 (https://doi.org/10.37766/inplasy2024.11.0074).

Internet of Things (IoT) application support system is key infrastructures and common software platform for various IoT applications at launch sites. The research studies the progress of IoT middleware related to academia and industry. On the basis of hybrid architecture, the paper proposes the architecture of the IoT application support system for the launch site. The architecture combines software with hardware and includes design and implementation scheme. It contributes to solving the problems of IoT application support system about the heterogeneity of embedded sensor devices and mobile terminals, mobility and network transformation, communication and data exchange, a fusion of different middleware systems, and implementing middleware support environment in launch site. In the domestic operating system and database environment, the personnel positioning application is realized by graphical programming and application deployment. The actual example verifies the availability of the architecture and presents the developing process of the IoT application support system in the launch site.